Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="articleColumn">Achaogen target raised to $29 at Needham (23.81)Needham raises their AKAO tgt to $29 from $19. AKAO hosted an R&D day yesterday, announced additional encouraging details around plazomicin Phase 3 results, and disclosed new oral cUTI program (C-Scape) that may enter Phase 3 development next yr. Recall plazomicin was superior to comparator on several endpts in Phase 3 CRE and cUTI trials. New data show mortality benefit through 60 days in CRE. Company has built strong case for use in CRE infections and firm has adjusted their model to reflect higher price ($20,000 vs. $15,000 course). Based on new sales est. New C-Scape candidate targets space w/ substantial unmet need and minimal competitive development, but they await details; Buy.</td> </tr></table>"